Kappa-CD28-T-cells

N/A

Report date: 2026/05/28 20:00:21

Base Information

Drug NameKappa-CD28-T-cells
Drug Alias NameKappa-CD28-T-cells
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsκ light chain of human immunoglobulins modulators
Targetsκ light chain of human immunoglobulins
Therapy Area/IndicationsBone Marrow NeoplasmsMultiple MyelomaLymphoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBaylor College Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesMethodist Hospital SystemTexas Children'S HospitalBaylor College Of Medicine
Inactive CompaniesN/A
Active IndicationsBone Marrow NeoplasmsMultiple MyelomaLymphoma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A